Skip to main content
Glama

Malwarebazaar

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Discloses several behaviors beyond annotations: graceful degradation when GLEIF/OpenFIGI is unavailable ('the EDGAR identifiers still return'), multi-candidate behavior ('returns `figi_candidates` to pick from'), and explicit `unresolved` output rather than omission. These are valuable traits not encoded in annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense, packed with parentheticals and semicolons, especially in the 'company' section. It is front-loaded with query examples and a first-use directive, but could be restructured for readability. Still, nearly every clause adds needed information.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description must explain return values, and it does: company returns CIK, ticker, company_name, LEI, ownership, FIGI, `figi_candidates`, `unresolved`; drug returns RxCUI, ingredient, brand, citation. It also covers edge cases like ISIN mapping and enrichment failure, so an agent has enough to call it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema already documents both parameters (100% coverage), and the description adds substantial guidance: accepted input formats for company (ticker, CIK, ISIN, name), drug brand/generic examples ('ozempic', 'metformin'), and a critical formatting warning to pass the ENTITY NAME ONLY for bonds. This exceeds the schema's descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb ('resolve') and resource ('user-spoken NAME' to canonical/official identifiers). It distinguishes itself from siblings by framing itself as the first step for name-to-ID lookup: 'Use FIRST whenever you have a name but need an ID.' The SUPPORTED TYPES breakdown further specifies company and drug entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Gives explicit usage context: 'Use FIRST whenever you have a name but need an ID' and notes it 'replaces 2-3 manual lookups.' However, it does not name any alternative tools or state when NOT to use it, so it stops short of full routing guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Malwarebazaar toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Several tools are near-duplicates: ask_pipeworx_beta is described as currently identical to ask_pipeworx, and ask_pipeworx_grounded is the same router with extra verification. Malware sample searches also overlap across search_family, search_tag, search_signature, and recent_samples, while ai_visibility_check is wrapped by scan_competitor_ai_presence.

Naming Consistency3/5

The set mostly uses snake_case and verb-first names like get_sample_info and validate_claim, which is helpful. However, conventions are mixed across ask_pipeworx*, polymarket_*, pipeworx_*, search_*, and noun-style names like recent_samples and entity_profile, so there is no single predictable pattern.

Tool Count2/5

36 tools is already over the comfortable range, but the bigger issue is that the server is named Malwarebazaar while only about five tools actually deal with malware. The remaining tools belong to an unrelated data-research, prediction-market, memory, and subscription platform, making the count inappropriate for the server's apparent purpose.

Completeness2/5

For the MalwareBazaar domain, the set covers metadata lookups and filtered sample searches but lacks sample submission, retrieval, or deeper analysis workflow. The rest of the tool surface targets unrelated domains, so there is no coherent, complete lifecycle for either malware intelligence or the broader feature set.

Resources